UBS Group’s BioCardia, Inc. Warrant BCDAW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10,030
| Closed | -$130 | – | 10426 |
|
|
2024
Q2 | $130 | Buy |
+10,030
| New | +$200 | ﹤0.01% | 9124 |
|
|
2024
Q1 | – | Sell |
-1
| Closed | – | – | 10253 |
|
|
2023
Q4 | $0 | Sell |
1
-21,206
| -100% | -$1.87K | ﹤0.01% | 10178 |
|
|
2023
Q3 | $5.3K | Buy |
+21,207
| New | +$11K | ﹤0.01% | 7381 |
|
|
2023
Q2 | – | Sell |
-45
| Closed | -$37 | – | 9937 |
|
|
2023
Q1 | $37 | Sell |
45
-1,055
| -96% | -$923 | ﹤0.01% | 9368 |
|
|
2022
Q4 | $913 | Buy |
1,100
+33
| +3% | +$21 | ﹤0.01% | 10036 |
|
|
2022
Q3 | $0 | Hold |
1,067
| – | – | ﹤0.01% | 11161 |
|
|
2022
Q2 | $0 | Hold |
1,067
| – | – | ﹤0.01% | 11171 |
|
|
2022
Q1 | $0 | Hold |
1,067
| – | – | ﹤0.01% | 11107 |
|
|
2021
Q4 | $1K | Sell |
1,067
-50
| -4% | -$64 | ﹤0.01% | 10064 |
|
|
2021
Q3 | $2K | Sell |
1,117
-237
| -18% | -$381 | ﹤0.01% | 9012 |
|
|
2021
Q2 | $2K | Buy |
+1,354
| New | +$1.92K | ﹤0.01% | 9003 |
|
|
2020
Q3 | – | Sell |
-90
| Closed | – | – | 8511 |
|
|
2020
Q2 | $0 | Buy |
+90
| New | +$86 | ﹤0.01% | 8459 |
|
|
2020
Q1 | – | Sell |
-1,105
| Closed | -$1K | – | 8530 |
|
|
2019
Q4 | $1K | Buy |
+1,105
| New | +$1.26K | ﹤0.01% | 7995 |
|
UBS Group's BCDAW Position: Q3 2024 in Review
UBS Group sold out of BioCardia, Inc. Warrant (BCDAW) in Q3 2024, closing a stake of 10,030 shares — an estimated $130 sold.
UBS Group first reported a position in BCDAW in Q4 2019 and held it in 13 quarters. The position peaked at $5.3K in Q3 2023. 0 funds tracked by Wall St. Rank hold BCDAW as of Q3 2024.
- UBS Group reported no remaining BioCardia, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 10,030 BioCardia, Inc. Warrant shares in Q3 2024, an estimated $130.
- UBS Group first reported a position in BioCardia, Inc. Warrant in Q4 2019 and held it in 13 quarters.
- UBS Group's BioCardia, Inc. Warrant position peaked at $5.3K in Q3 2023.
- 0 funds tracked by Wall St. Rank held BioCardia, Inc. Warrant as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.